1. Home
  2. BAND vs IMMX Comparison

BAND vs IMMX Comparison

Compare BAND & IMMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Bandwidth Inc.

BAND

Bandwidth Inc.

HOLD

Current Price

$63.79

Market Cap

771.9M

Sector

Technology

ML Signal

HOLD

Logo Immix Biopharma Inc.

IMMX

Immix Biopharma Inc.

HOLD

Current Price

$8.11

Market Cap

629.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BAND
IMMX
Founded
2000
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Medicinal Chemicals and Botanical Products
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
771.9M
629.3M
IPO Year
2017
2021

Fundamental Metrics

Financial Performance
Metric
BAND
IMMX
Price
$63.79
$8.11
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
4
5
Target Price
$24.50
$19.20
AVG Volume (30 Days)
1.1M
1.4M
Earning Date
04-30-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$204,113,000.00
N/A
Revenue This Year
$15.16
N/A
Revenue Next Year
$6.18
N/A
P/E Ratio
N/A
N/A
Revenue Growth
25.26
N/A
52 Week Low
$12.50
$1.94
52 Week High
$75.98
$11.61

Technical Indicators

Market Signals
Indicator
BAND
IMMX
Relative Strength Index (RSI) 57.34 39.74
Support Level $14.27 $3.98
Resistance Level N/A $10.61
Average True Range (ATR) 5.94 0.66
MACD -1.50 -0.07
Stochastic Oscillator 35.40 21.23

Price Performance

Historical Comparison
BAND
IMMX

About BAND Bandwidth Inc.

Bandwidth Inc is cloud-based communications platform-as-a-service (CPaaS) provider that enables enterprises to create, scale and operate voice or messaging communications services across any mobile application or connected device. Company earns revenue through the sale of communications services offered through Application Programming Interface software solutions to enterprise customers. The majority of its revenue is generated from usage-based fees that includes voice communication and messaging communication that traverse the platform and network.

About IMMX Immix Biopharma Inc.

Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. Its product candidates include CAR-T NXC-201 for autoimmune diseases, and IMX-110 for treatment of soft tissue sarcoma.

Share on Social Networks: